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Abstract
Introduction: Both murine and human genome-wide association studies have implicated peptidyl arginine
deiminase (PAD4) as a susceptibility gene in rheumatoid arthritis (RA). In addition, patients with RA commonly have
autoantibodies which recognize PAD4 or and/or citrullinated peptides. This study aims to evaluate the role of
PAD4 in the effector phase of arthritis.
Methods: PAD4 knock out (KO) and wild type (WT) C57BL/6J mice were injected with K/BxN sera to induce
disease. Progression of disease was monitored by measuring paw and ankle swelling and clinical indexes of
disease, and pathogenesis was assessed by indexing of clinical progression on paws collected from WT and PAD4
KO mice injected with K/BxN serum. PAD4 activity was determined by visualization of neutrophil extracellular traps
(NETs) and immunohistological analysis of histone citrullination.
Results: PAD4 activity is readily detectable in the inflamed synovium of WT but not PAD4 deficient animals, as
demonstrated by histone citrullination and NET formation. However, PAD4 WT and KO animals develop K/BxN
serum transfer disease with comparable severity and kinetics, with no statistically significant differences noted in
clinical scores, swelling, joint erosion or joint invasion.
Conclusions: PAD4 WT and KO mice develop disease in the K/BxN serum transfer model of arthritis with similar
severity and kinetics, indicating that PAD4 is dispensable in this effector phase model of disease.
Introduction
Citrulline-containing proteins are generated through
posttranslational modification of arginine residues in a
reaction catalyzed by the Ca2+-dependent peptidyl argi-
nine deiminases (PADs). There are five PAD family
members, but only PAD2 and PAD4 expression are clo-
sely linked with inflammation in RA synovial tissue
[1,2]. While PAD2 is broadly expressed across tissue
types, including by immune cells, PAD4 exhibits an
expression pattern restricted to immune cell types, in
particular macrophages and granulocytes [1,3].
Rheumatoid arthritis (RA) is a chronic autoimmune
disease characterized by systemic inflammation, chronic
synovitis, joint destruction and bone loss, affecting
approximately 2% of the world population [4]. Plasma
and synovial biopsy specimens from patients with RA
contain high levels of citrullinated proteins [5,6], and
anti-citrullinated peptide antibodies (ACPAs) exhibit
high specificity and sensitivity as diagnostic markers of
the disease [7]. Anti-citrulline peptide antibodies can
appear before disease onset and correlate with the most
erosive form of RA [8].
PAD4 shows elevated expression in RA [1,9], and RA
patients generate high affinity anti-PAD4 autoantibodies
which correlate with more severe disease [10-12].
Further, variants of PAD4 are linked to RA in several
Japanese and Korean cohorts, although this association
has not held up in most North American and European
study groups, despite the prevalence of ACPA in all eth-
nic groups [13]. Thus, the development of autoantibo-
dies to citrullinated epitopes and PAD4 and elevated
PAD4 expression in RA, suggests that aberrant PAD
activity may contribute to disease pathogenesis.
The offspring of an intercross between the KRN TCR
transgenic mouse specific for a bovine RNase (42-56) in
the context of I-Ak and the I-Ag7-expressing non-obese
diabetic (NOD) background, spontaneously develop a
progressive, inflammatory joint disease with features
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similar to human RA (K/BxN mice) [14]. The autoanti-
gen in this model is glucose-6-phosphate isomerase
(GPI), a ubiquitous cytoplasmic enzyme [15]. Treatment
with the sera of K/BxN mice or purified anti-GPI auto-
antibodies is sufficient to transfer disease to healthy ani-
mals, even in animals devoid of B and T cells [14,15].
Because autoantibodies are passively transferred, this
model focuses on immune recruitment and joint
destruction (effector phase), rather than the breaking of
immune tolerance (priming phase). Innate immune sig-
nals are critical for this model because mice deficient in
the alternative complement pathway, the C5a receptor,
the CXCR2 chemokine receptor, interleukin-1 receptor
(IL-1R), and myeloid differentiation primary response
protein (MyD88) are resistant to disease [14,16,17].
Further, arthritis was not sustained in toll-like receptor
4 (TLR4) mutant mice [16]. Passively transferred arthri-
tis also requires the presence of mast cells and neutro-
phils [18-21].
Neutrophils are among the first immune cell types to
accumulate during an inflammatory response [22]. In
response to inflammatory stimuli, neutrophils decon-
dense their chromatin and actively expel their DNA-
producing neutrophil extracellular traps (NETs) that are
decorated with granular and nuclear proteins, including
citrullinated histones [23,24]. Incubation of neutrophils
with phorbol 12-myristate 13-acetate (PMA), hydrogen
peroxide, lipopolysaccharide (LPS), bacteria, and yeast
induces NET formation [24-27]. Our lab and others
have shown that PAD4 is essential for the production of
NETs and NET-associated histone citrullination
[24,25,27]. PAD4-mediated histone citrullination is
thought to play a mechanical role in NET formation,
where the conversion of positively charged arginine resi-
dues into the neutral citrulline amino acid by PAD4
promotes chromatin decondensation [24]. PAD4-
mediated NET formation is critical for controlling at
least a subset of bacterial infections because PAD4-defi-
cient mice are more susceptible to infectious disease in
a necrotizing fasciitis model [27].
NET formation, although critical for the full activation
of the innate immune response [27], has also been
implicated in inflammatory disease pathogenesis, includ-
ing the autoimmune disorder lupus [28], cystic fibrosis
([29-31], sepsis [32], and thrombosis [33]. Interestingly,
it has been suggested that NETs offer a possible
mechanism by which PAD4 may be liberated from the
cell to generate citrullinated antigens and exacerbate
inflammation [9,34]. Recently, Dwievedi et al. described
hypercitrullination in neutrophils from arthritic patients,
as well as the specific reactivity of arthritic serum to
activated neutrophils and citrullinated histones [34]. It is
unclear whether PAD4-induced NET formation plays a
role in the RA inflammatory process.
Recently, using a genome-wide screen of mice, John-
sen et al. identified the region containing Padi4 as being
putatively involved in the development of K/BxN arthri-
tis and demonstrated that increases in the transcripts of
both PAD2 and PAD4 correlates with increased severity
of disease [35]. Because the K/BxN model is neutrophil
dependent, PAD4 activity is required for NET formation
and PAD4 overexpression correlates with rheumatoid
arthritis in patients, we sought to determine the extent
to which PAD4 would contribute to the effector phase




PAD4 knockout (KO) mice were generated as previously
described [25]. KRN T cell receptor (TCR) transgenic
mice were a gift from Drs D Mathis and C Benoist
(Harvard Medical School, Boston, MA) and the Institut
de Génétique et de Biologie Moléculaire et Cellulaire
(Strasbourg, France) [14]. Wildtype C57BL/6J mice were
obtained from the Scripps Research Institute rodent
breeding colony. Experiments were reviewed and
approved by the Scripps Research Institute Institutional
Animal Care and Use Committee.
Induction of serum-transfer arthritis
K/BxN serum was collected from 6- to 10-week-old K/
BxN mice and pooled, and 5- to 6-week-old male PAD4
KO or C57BL/6J WT control mice were injected intra-
peritoneally (i.p.) with 150 μL pooled K/BxN sera on
days 0 and 2. Caliper measurements of paw and ankle
swelling were taken daily. Clinical indexes of swelling
were assigned according to previously described criteria
[37]. Animals were sacrificed at day 5 or day 10 and the
hind paws were prepared for fluorescence microscopy
or histology.
Fluorescence Microscopy of Histone Citrullination and
NETs
Hind paws were removed from euthanized animals at
day 5, post K/BxN serum injection. Ankle joints were
exposed and flushed with Roswell Park Memorial Insti-
tute media (RPMI) with 0.5% BSA. Peripheral blood was
collected by eye bleed. Erythrocytes were lysed in 10
mM KHCO3, 150 mM NH4Cl NS 1 mM EDTA and
remaining cells were washed with PBS. Ankle or periph-
eral blood cells were attached to poly-lysine-coated glass
coverslips and fixed in 4% paraformaldehyde (PFA) with
1% Nonidet P-40 (NP-40) and 0.5% Triton X-100 in
PBS. Slides were blocked with 2.5% BSA and 5% goat
serum in PBS with 0.5% Tween-20. Citrullinated his-
tones were detected with anti-H4Cit3 (Millipore, Biller-
ica, MA, USA) and goat anti-rabbit Alexa488 (Life
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Technologies, Grand Island, NY, USA). DNA was
labeled with DAPI (Sigma, St. Louis MO, USA). Cover-
slips were mounted with Prolong Gold Antifade reagent
(Life Technologies, Grand Island, NY, USA).
Histology
Hind paws were removed from euthanized animals,
fixed in 4% paraformaldehyde in PBS overnight and dec-
alcified in 0.375 M EDTA pH 7.5 for 3 weeks. Paws
were embedded in paraffin and affixed to slides for
immunohistochemistry or pathological analysis by The
Scripps Research Institute Histology Core. For immuno-
histochemistry, paraffin-embedded slices on slides were
deparaffinized with xylene and rehydrated. Antigens
were unmasked by boiling in PBS pH 7.4. Slides were
blocked with 10% normal goat serum and endogenous
peroxidases were quenched with 3% peroxide in metha-
nol. Sections were then incubated with anti-H4cit3 or
control rabbit immunoglobulin (IgG) antibodies (Milli-
pore, Billerica, MA, USA). Labeling was detected with a
biotinylated anti-rabbit secondary antibody (Life Tech-
nologies, Grand Island, NY, USA), Vectastain Elite ABC
reagent (Vector Labs, Burlingame, CA, USA) and DAB
(Life Technologies, Grand Island, NY, USA). Slides were
counterstained with Shandon Harris hematoxylin
(Thermo Scientific, Waltham, MA, USA). Histopatholo-
gical scoring was performed blinded as described pre-
viously [16]. Briefly, ankles of arthritic mice were given
scores of 0 to 5 for inflammation, according to the fol-
lowing criteria: 0 = normal; 1 = minimal infiltration of
inflammatory cells in the periarticular area; 2 = mild
infiltration; 3 = moderate infiltration; 4 = marked infil-
tration; and 5 = severe infiltration. Knees of arthritic
mice were given scores of 0 to 5 for bone resorption,
according to the following criteria: 0 = normal; 1 =
minimal (small areas of resorption, not readily apparent
on low magnification); 2 = mild (more numerous areas
of resorption, not readily apparent on low magnification,
in trabecular or cortical bone); 3 = moderate (obvious
resorption of trabecular and cortical bone, without full-
thickness defects in the cortex; loss of some trabeculae;
lesions apparent on low magnification); 4 = marked
(full-thickness defects in cortical bone and marked tra-
becular bone loss; without distortion of the profile of
the remaining cortical surface) and 5 = severe (full-
thickness defects in the cortical bone and marked trabe-
cular bone loss with distortion of the profile of the
remaining cortical surface).
Results
NETs are found in the joints of K/BxN serum-transfer
animals
Neutrophils are the predominant infiltrating cell type in
the K/BxN serum transfer arthritis model and are found
within synovium throughout the serum-transfer during
the course of arthritis disease [17,20]. Importantly,
PAD4 is highly expressed in the granulocyte lineage,
including neutrophils [3] and is known to be required
for the formation of Neutrophil Extracellular Traps
(NETs) [25,27]. NETs have been shown to occur in sev-
eral inflammatory disease states, including lupus [28],
sepsis [32,33] and cystic fibrosis [29-31] and are thought
to serve as a means for PAD4 to enter into the extracel-
lular space, where it may citrullinate substrates and
exacerbate inflammation [9]. NETs are common to sev-
eral other inflammatory disease states, but to our knowl-
edge, NET structures, per se, have not been reported in
patients with RA or in murine models of disease. How-
ever, recently, Dwivedi et al. reported that serum IgGs
from patients with Felty’s syndrome react to NETs and
preferentially to citrullinated histones over unmodified
histones, indicating that NET markers, and thus NETs,
may be present in Felty’s syndrome [34]. Since ACPA
and anti-PAD4 antibodies are frequently found in
patients with RA [9], it is presumed that aberrant PAD
activity influences the priming phase of arthritis. How-
ever, it is unknown where PAD4 may also regulate the
effector phase of arthritis. We therefore considered
whether PAD4-mediated NET formation could contri-
bute to K/BxN-induced inflammation.
To determine whether NET formation occurs in the
K/BxN serum transfer model, fluorescence microscopy
of flushed synovial cells was performed. PAD4 WT and
KO mice were injected with K/BxN serum on days 0
and 2. Mice were sacrificed at day 5 to collect synovial
and peripheral blood cells. Cells flushed from the ankles
of arthritic WT mice displayed citrullinated histones, a
hallmark of PAD4 activity, and NET formation, while
those from PAD4 KO mice exhibited no detectable his-
tone citrullination or NET formation, as detected by
anti-H4Cit3 and 4’,6-diamidino-2-phenylindole (DAPI)
(Figure 1A). As expected, few cells could be flushed
from the ankles of WT control mice, and none were
observed to have citrullinated histones or to form NETs
(Figure 1A). Histone citrullination, but not NET forma-
tion, was detected in the peripheral blood of WT K/
BxN mice, but not WT control mice (Figure 1B).
Neither histone citrullination nor NET formation was
found in control mice of either genotype (Figure 1B).
Thus, NET formation does occur in the K/BxN model
of the effector phase of RA and is specific for the
arthritic ankle.
There is abundant PAD4 activity during K/BxN serum-
transferred arthritis
PAD4 is found in the synovial fluid and infiltrating syno-
vial cells of patients with RA [9,38,39]. In the K/BxN
serum transfer model, elevated expression of PAD4 in the
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Figure 1 Wild type (WT) K/BxN serum transfer mice generate synovial neutrophil extracellular traps (NETs). Mice were injected with K/
BxN serum on days 0 and 2 and sacrificed on day 5. Synovial cells were flushed from the ankle joint (A) and peripheral blood was collected
from the venous plexus of arthritic or healthy mice (B) and stained with antibodies to citrullinated histone H4 and 4’,6-diamidino-2-phenylindole
(DAPI). Histone citrullination and NETs were readily detectable in the arthritic joints of WT mice, but were not observed in peptidyl arginine
deiminase 4 knockout (PAD4 KO) K/BxN mice or WT healthy controls (A). Histone citrullination was present in the peripheral blood of WT K/BxN
mice, however, no NET formation was observed. Images were taken at 80× magnification and are representative of at least three independent
experiments with two mice per experimental group.
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spleen correlates with the severity of arthritis [35]. To
determine whether PAD4 enzymatic activity was a hall-
mark of the effector phase of arthritis, immunohistochem-
istry of the PAD4-dependent citrullinated histone H4 was
performed [25,27]. Mice were injected with K/BxN serum
on days 0 and 2. On day 10, mice were sacrificed, hind
limbs were harvested and prepared for histology, and tis-
sue sections were immunostained for citrullinated histone
H4. WT mice displayed robust histone H4 citrullination,
with the most prominent staining in infiltrating cells
within the synovial sublining, which were most likely neu-
trophils. This modification was dependent upon PAD4
because PAD4 KO mice exhibited no staining for citrulli-
nated histone H4 (Figure 2). These data demonstrate that
robust PAD4 activity is present within the ankle joint dur-
ing the effector phase of arthritis.
PAD4 deficiency does not protect against disease in
serum-transferred arthritis
To test the importance of PAD4 in the effector phase of
arthritis, we injected K/BxN serum into age-matched
WT and PAD4 KO C57BL6/J mice on days 0 and 2 and
monitored disease progression. Measurements of paw
swelling and clinical disease index were taken daily for
ten days. Paw swelling was calculated as the percentage
increase in paw size compared to day 0. The onset of
disease and the overall kinetics of disease were similar
between WT and PAD4 KO mice (Figure 3). Although
there was a trend toward reduced swelling and lower
disease scores in PAD4 KO mice, the differences were
small and did not reach statistical significance (Figure
3). Disease is transient in the serum transfer model. We
found that PAD4 KO mice recovered with similar
kinetics to WT mice (data not shown). Thus, PAD4 is
not required for the development or maintenance of K/
BxN-serum transferred arthritis.
Comparable histological features between arthritic WT
and PAD4-deficient mice
Although WT and PAD4 KO mice exhibited a similar
level of inflammation, the degree of joint destruction
and inflammatory infiltrates could be affected by PAD4
deficiency. Thus, hind limbs were harvested from WT
and PAD4 KO mice on day 10 following serum transfer.
Histological evaluation by an investigator blinded to the
animal genotype for degree of inflammation and erosion
of bone was performed. Inflammation and bone erosions
were quantified by scoring joint sections on a 0 to 5
scale. Hematoxylin and eosin stain (H&E) sections of
the ankle joints revealed a comparable, moderate degree
of inflammatory cell infiltration in WT and PAD4 KO
mice (Figure 4 and Table 1). In healthy mice, the
Figure 2 Peptidyl arginine deiminase 4 (PAD4) activity is detected in K/BxN arthritic legs in wild type (WT) but not PAD4 knockout
(KO) mice. PAD4 activity was measured by immunohistochemical detection of citrullinated histone H4 (H4Cit3). WT and PAD4 KO mice were
immunized with pooled K/BxN serum as described. Mice were sacrificed 10 days post injection (p.i.) and their legs prepared for histology.
Sections were blocked in goat serum and probed with either anti-H4Cit3 antibody or isotype control. Images were taken at 80× magnification.
Specific staining of citrullinated histone H4 was apparent on WT but not PAD4 KO slides and is representative of at least 4 independent
experiments.
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Figure 3 Progression of K/BxN serum transfer arthritis in peptidyl arginine deiminase 4 (PAD4) wild type (WT) (n = 29) and knockout
(KO) (n = 27) mice. WT and PAD4 KO mice were immunized with pooled K/BxN serum as described and monitored for signs of disease
severity for 10 days. Paw swelling (A) is expressed as the average percent size increase of four paws and two ankles compared to day 0
measured by caliper. Clinical indexes (B) of 0 to 3 were assigned for each paw as previously described [37]. Data are combined from three
independent experiments and represented as the average ± standard error of the mean (SEM). No statistically significant difference in the
progression of K/BxN disease was apparent between WT and PAD4 KO mice.
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synovium consists of a single layer. Both WT and PAD4
KO mice developed a proliferative synovial response fol-
lowing K/BxN serum treatment. Furthermore, WT and
PAD4 KO mice exhibited a similar level of bone erosion.
Therefore, the histological features of the K/BxN serum-
mediated model of arthritis are not altered in the
absence of PAD4.
Discussion
In this study, we find that the PAD4 enzyme is active
within the joint tissue of arthritic mice and leads to
NET formation. However, the disease course and histo-
logical features of the arthritic joints following K/BxN
serum injection were comparable between WT and
PAD4-deficient mice, demonstrating that PAD4 is not
required for the effector phase of arthritis. Our data are
consistent with the findings by Willis et al., showing
that the PAD inhibitor Cl-amidine provides therapeutic
benefit in the collagen-induced arthritis model but has
no benefit when arthritic disease is induced by the
administration of anti-collagen antibodies. Collagen
induced arthritis and injection of anti-collagen antibo-
dies represent the priming and effector phases of dis-
ease, respectively. We have now shown that PAD4 is
active but not required for disease, in another model of
the effector phase, the K/BxN serum transfer model,
which is consistent with the finding that PAD inhibitors
have no effect on disease when induced by administra-
tion by anti-collagen antibodies [40]. Interestingly, Cl-
amidine preferentially inhibits PADs 1 and 4 over
PAD3, and its effects have not been reported for PADs
2 or 6 [41].
Indeed, Johnsen et al. identified the Padi locus, which
contains the PAD4 gene along with the genes for PADs
1, 2, 3, and 6, as being linked with disease in the K/BxN
serum transfer model [35]. PAD2 and PAD4 are the
most likely candidates to regulate the effector stage of
arthritis as they are both expressed in immune cell
types, whereas the expression of PADs 1, 3, and 6 are
restricted to the epidermis, hair follicle, and oocyte,
respectively. Indeed, increased splenic expression of
both PAD2 and PAD4 correlated with disease severity
in the K/BxN model [35]. Further, within the PAD
region, a SNP found within the Padi2 locus showed the
most significant association with disease [35]. We specu-
late that the loss of PAD2 and PAD4 together may pro-
duce a more apparent phenotype in the K/BxN model
[40]. PAD2 KO mice have been reported [42], however
the PAD2 and PAD4 loci are approximately 1 centimor-
gan apart, and therefore, the recombination frequency
between the targeted PAD2 and PAD4 alleles would be
Figure 4 Pathological evaluation of immune invasion and joint destruction in wild type (WT) and peptidyl arginine deiminase 4
knockout (PAD4 KO) K/BxN mice. WT (n = 27) and PAD4 KO (n = 29) animals were immunized with pooled K/BxN serum as described,
sacrificed at day 10 post injection (p.i.) and their legs prepared for histology. Hematoxylin- and eosin-stained stained slides were scored blinded
by a trained observer for immune cell invasion (0 to 5) and joint erosion (0 to 5). Pictures were taken at 40× magnification and are
representative of the average scores for invasion (4) and erosion (2), shown in Table 1. Areas of immune cell invasion into cartilage of joint
(closed arrows) and bone reabsorption (open arrows) are highlighted.
Table 1 Clinical scores of inflammation and joint erosion
in wild-type and peptidyl arginine deiminase 4 knockout
K/BxN mice
Group Inflammation (0 to 5)
(mean ± STDEV)
Joint Erosion (0 to 5)
(mean ± STDEV)
WT 3.4 ± 1.3 2.5 ± 1.4
PAD4 KO 3.6 ± 1.0 2.2 ± 1.7
Pathological scoring of immune invasion and joint destruction in wild type
(WT) and peptidyl arginine deiminase 4 knockout (PAD4 KO) K/BxN mice. WT
(n = 27) and PAD4 KO (n = 29) animals were immunized with pooled K/BxN
serum as described, sacrificed at day 10 post injection (p.i.), and their legs
prepared for histology. Hematoxylin- and eosin-stained slides were scored
blinded by a trained observer for immune cell invasion (0 to 5) and joint
erosion (0 to 5). Results are represented as the average of 27 and 29 mice per
genotype ± standard deviation. Average scores for joint invasion and erosion
were similar in WT and PAD4 KO mice.
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quite small, making the generation of Padi2/Padi4 DKO
mice unlikely. While our data demonstrate that PAD4 is
not required for the development of the K/BxN serum-
transfer model, it is possible that there might be redun-
dant activity of other PADs or they may independently
contribute to the pathogenesis of antibody-mediated
arthritis.
The blood of RA patients contains autoantibodies
directed against a number of self-antigens. Many auto-
antibodies in RA are directed against citrullinated pro-
teins. In fact, the presence of anti-citrulline antibodies is
a better predictor of RA than rheumatoid factor [43].
Variants of PAD4 are linked to RA in several Japanese
and Korean cohorts, and the mRNA of a disease-asso-
ciated allele is more stable than a non-disease associated
allele [36,44]. It has been proposed that PAD4 is linked
to RA because PAD4 citrullination of peptides leads to a
breakdown in tolerance to self-antigens [43,45]. In sup-
port of this, treatment of mice with the PAD inhibitor
Cl-amidine in the collagen-induced arthritis (CIA)
model reduces the levels of citrulline found in the
serum and synovial tissue, diminishes the formation of
autoantibodies, and ameliorates disease [40]. Thus, it
will be interesting to determine whether the effects of
Cl-amidine are attributable to PAD4 activity by examin-
ing the susceptibility of PAD4 KO mice to arthritic dis-
ease using the CIA model.
Incubation of human neutrophils with lipopolysac-
charides (LPS), TNFa, N-formyl-methionine- leucine-
phenylalanine (fMLP), or lipoteichoic acid and murine
neutrophils with LPS or bacteria, has been shown to
induce histone deimination and NET formation, mark-
ing PAD4 activity [24-27]. Further, we detected deimi-
nated histone H4 in lung leukocytes isolated from
influenza-infected mice [25]. In this report, we find that
PAD4 activity is readily detected within the affected
arthritic joint. In WT mice receiving K/BxN serum, the
presence of deiminated histones corresponded primarily
to the infiltrating cells of the joint sublining, which is
consistent with the expression pattern of PAD4 found
in patients with RA [46,47]. The stimulus that induces
PAD activity during autoimmune-mediated inflamma-
tion is undefined. However, the LPS receptor TLR4, has
been linked to animal models of arthritis, perhaps
because of the activation of TLR4 by endogenous
ligands, such as Tenascin-C [16,48,49].
NETs possess potent microbicidal capabilities but have
also been implicated in chronic inflammatory diseases
[23,50]. NET formation is linked to cystic fibrosis
[29-31]. Similarly, the formation of NETs contributes to
endothelial and tissue injury during sepsis [32]. In auto-
immune small-vessel vasculitis, anti-neutrophil cyto-
plasm antibodies (ANCA) trigger the formation of
NETs, promoting necrotic inflammation of the blood
vessels [51]. Systemic lupus erythematous (SLE) is a sys-
temic autoimmune disease characterized by the forma-
tion of pathogenic immune complexes. When activated
by autoantibodies, neutrophils isolated from patients
with SLE produce NETs, exposing immunostimulatory
proteins and potential autoantigens and leading to the
induction of Type I interferons by plasmacytoid dendri-
tic cells [28,52,53]. Collectively, these results support the
notion that NET production can contribute to disease
pathogenesis in inflammatory conditions. While hyperci-
trullination of neutrophil histones has been reported in
patients with RA [34], it is unclear whether NETs have
a role in RA inflammation. Our results suggest that
PAD4 activity and subsequent NET formation is present
in the K/BxN serum transfer model, but is not required
for this model of effector phase of disease.
Our data demonstrate that PAD4 is not necessary for
the antibody-dependent, effector stage of arthritis. It is
also possible that compensation by other PAD family
members, PAD2 in particular, may mask the function of
PAD4 in arthritis, although we note that PAD2 expres-
sion is not upregulated in PAD4-deficient neutrophils
[25]. Finally, since the Padi locus is linked to disease
severity in the K/BxN serum transfer model, it may be
necessary to eliminate several PAD family members,
either by targeting multiple locations within the PAD
locus or by combining treatment with specific PAD
inhibitors with targeted PAD alleles. Further studies will
be necessary to dissect the role of PAD4 in the priming
phase of arthritis.
Conclusions
NET formation is known to correlate with inflammatory
disease [28,32,33,52,53], however NET formation has
not been reported in RA. NET formation is dependent
on PAD4 and the association between PAD4 and RA is
well-established [9]. In this report, we show that in the
K/BxN murine model of arthritis, which emulates the
effector phase of disease, PAD4 activity and NET forma-
tion are detected. PAD4 activity is not, however,
required for disease, as PAD4 WT and KO mice develop
K/BxN-induced arthritis with similar severity and
kinetics. Overall our data indicate that PAD4 is dispen-
sable in this model. However this does not eliminate a
role for PAD4 in the priming phase of disease. Future
studies will consider the role of PAD4 in priming phase
models of RA, including the CIA model.
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